PAA21 DEVELOPMENT OF A COST-UTILITY MODEL FOR COMPARING GINA STEP 3 ASTHMA MEDICATIONS BASED ON UTILITY AND SAFETY DATA DERIVED FROM A LARGE HEAD-TO-HEAD TRIAL OF MONTELUKAST AND SALMETEROL

Subjects

Subjects :

medicine.medical_specialty
business.industry
Health Policy
Public Health, Environmental and Occupational Health
medicine.disease
Cost utility
medicine
Physical therapy
Head (vessel)
Large head
Salmeterol
business
Montelukast
medicine.drug
Asthma

Details

ISSN :

10983015

Volume :

10

Database :

OpenAIRE

Journal :

Value in Health

Accession number :

edsair.doi.dedup.....3129b6f13887cd4b29db0097e2d6a802

Full Text :

https://doi.org/10.1016/s1098-3015(10)65413-7